Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad RBM Joins Institut Pasteur in the Global Fight Against Tuberculosis

GlobeNewswire January 20, 2015

Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors

GlobeNewswire January 8, 2015

Myriad Genetics to Present at the 2015 J.P. Morgan Annual Healthcare Conference

GlobeNewswire January 5, 2015

Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience

GlobeNewswire December 22, 2014

Myriad Receives FDA Approval of BRACAnalysis CDx(TM) as Companion Diagnostic for Lynparza(TM) (olaparib) in Ovarian Cancer Patients

GlobeNewswire December 19, 2014

Three New Myriad Studies Highlighted at 2014 San Antonio Breast Cancer Symposium

GlobeNewswire December 9, 2014

Myriad to Present Eight Studies at 2014 San Antonio Breast Cancer Symposium

GlobeNewswire December 3, 2014

Study Shows Prolaris(R) Could Save Healthcare System $6 Billion Over 10 Years

GlobeNewswire December 2, 2014

TESARO and Myriad Announce Companion Diagnostics Collaboration

GlobeNewswire November 20, 2014

Crescendo Bioscience Highlights New Clinical Data on Vectra(R) DA at ACR

GlobeNewswire November 19, 2014

Crescendo Bioscience to Feature New Data on Vectra(R) DA at 2014 ACR Meeting

GlobeNewswire November 10, 2014

Myriad myPath(TM) Melanoma Improves Diagnosis and Treatment Plans

GlobeNewswire November 7, 2014

Myriad Genetics Reports Fiscal First Quarter 2015 Financial Results

GlobeNewswire November 4, 2014

Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM)

GlobeNewswire November 3, 2014

Myriad Genetics to Present at the 2014 Credit Suisse Annual Healthcare Conference

GlobeNewswire October 29, 2014

Myriad Announces Inclusion of Prolaris(R) Test in NCCN Guidelines

GlobeNewswire October 27, 2014

Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe

GlobeNewswire October 24, 2014

Myriad Genetics to Announce 1Q15 Financial Results on November 4, 2014

GlobeNewswire October 21, 2014

Myriad Receives Draft Medicare Coverage for Prolaris(R)

GlobeNewswire October 17, 2014

Myriad Appoints R. Bryan Riggsbee as Chief Financial Officer

GlobeNewswire October 8, 2014
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested